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Simultaneous spectrofluorometric analysis of tablets containing 
hydrochlorothiazide combined with timolol maleate or amiloride 
hydrochloride
Green and sensitive spectrofluorometric methods have 
been developed and validated for the determination of 
timolol maleate (TML)/hydrochlorothiazide (HCT) and 
amiloride hydrochloride (AMH)/hydrochlorothiazide in 
tablets. The proposed spectrofluorometric procedures were 
found to be linear in the range of 4–12, 5–35 and 0.025–0.2 
mg L–1 for HCT, TML and AMH, resp. The excitation and 
emission wavelengths for HCT, TML and AMH at room 
temperature were 270 and 375, 295 and 435, 330 and 415 nm, 
resp. The methods were validated with respect to ICH 
guidelines. The AMH showed higher sensitivity with lower 
values of LOD and LOQ values compared to HCT and TML. 
The proposed methods were applied to two pharmaceutical 
formulations; the method for HCT and AMH has proven as 
reliable assaying method, whereas the method for TML, 
when combined with HCT, is applicable to screening semi-
quantitative analyses.
Keywords: hydrochlorothiazide, amiloride hydrochloride, 
timolol maleate, fixed-dose combinations, spectrofluoro-
metry, assaying, screening
Moduretic (Uniretic) and Timolide are examples of fixed-dose drug combinations 
that contain beta-adrenergic blocking agents and hydrochlorothiazide (HCT) as a second 
active component. Moduretic contains amiloride hydrochloride (AMH) with HCT. AMH 
is N-amidino-3,5-diamino-6-chloropyrazine-2-carboxamide hydrochloride, which has an 
empirical formula C6H9Cl2N7O. It is a potassium preserving diuretic with antihyperten-
sive activity. It is employed as additional treatment with thiazide diuretics to aid in the 
restoration of normal serum potassium levels and to prevent the development of hypoka-
lemia (1). HCT is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide. 
Its empirical formula is C7H8ClN3O4S2. The HCT is a diuretic agent, which is used in 
the treatment of oedema associated with congestive heart failure and renal and hepatic 
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Timolide is supplied as tablets containing timolol maleate (TML) and HCT. TML is 
(2S)-1-[(1,1-dimethyl-ethyl)amino]-3-[[4-(morpholin-4-yl)-1,2,5-thiadiazol-3-yl] oxy] pro-
pan-2-ol (Z)-butenedioate. It has a molecular formula C13H24N4O3S × C4H4O4 with a molar 
mass of 432.49. TML is a non-cardioselective beta-blocker; it is widely used as standard 
medication for intraocular pressure (glaucoma) by preventing the production of aqueous 
humor. It is also an active treatment for hypertension, angina pectoris and myocardial 
infarction (3–5).
In recent years, increasing attention has been focused on the simultaneous determina-
tion of binary mixture of AMH/HCT. Sophisticated instrumentation and techniques were 
applied for the quantitative analysis. Availability of apparatus, high-cost organic solvents 
and high cost of such analyses limited their routine use. Some of these techniques are 
spectrophotometric absorbance ratio method (6), ratio spectra derivative spectrophoto-
metry coupled HPLC (7, 8), differential pulse polarography coupled with partial least 
squares (9), and the reversed-phase HPLC method (10–12). 
Few analytical techniques have been reported for the analysis of HCT and TML com-
binations, for example, derivative and derivative-ratio spectrophotometry (8) and the flow-
injection method (13).
Analysis of AMH and HCT combinations and, even more, in the combination with 
TML or another component was reported (6, 7). Chemometric procedures such as classical 
least squares (CLS), principal components regression (PCR) and partial least squares were 
successfully applied for the analysis of synthetic samples and commercial tablet prepara-
tions containing AMH and HCT alone, or containing AMH, HCT in association with 
 ate nolol (ATL) or TML (6). Moreover, analysis of combinations of three components, 
AMH, HCT and ATL in combined formulations was carried out using derivative spectro-
scopy (7).
This work was intended to demonstrate the analysis of the aforementioned analytes 
in combined formulations in the aqueous medium, to meet the requirements of green 
chemistry (14). It was devoted to the application and development of spectrofluorometric 




Perkin Elmer LS45 Fluorescence Spectrometer was used for fluorescence measure-
ments using a 1-cm quartz cuvette, part number B0631107 (Perkin Elmer, USA). The data 
analyses were carried out using a Flwinlab software, version 4.00.03. All measurements 
were carried out at 22 ± 2 °C.
Materials
The HCT (purity 99.2 %) was purchased from Unichem Laboratories Limited, India. 
AMH was supplied by Bal Pharma Limited, India (purity 99 %). TML was supplied by 
Supriya Lifescience Ltd., India (purity 99 %). Magnesium stearate (Sigma-Aldrich, USA), 
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povidone (VWR, USA), lactose (VWR), corn starch (Avonchem Limited, UK), colloidal 
silicon dioxide (Sigma-Aldrich), cellulose (Fisher Scientific SAS, France), Insacoat II IA-
30103 colorant (United Pharmaceuticals, Jordan), FD&C Blue 2 colorant (Hikma Pharma-
ceuticals, Jordan) were used to prepare placebo powder.
Commercial tablets Uniretic® ‒ amiloride hydrochloride (5 mg) and hydrochlorothia-
zide (50 mg) (United Pharmaceuticals, Jordan) and Timolide® ‒ timolol maleate (10 mg) and 
hydrochlorothiazide (25 mg) (Merck Inc., USA), were analyzed. The Uniretic excipients 
provided by the manufacturer were: povidone, lactose, corn starch, colloidal silicon diox-
ide, Insacoat II IA-30103 colorant and magnesium stearate. Timolide® excipients were cellu-
lose, starch, magnesium stearate and FD&C Blue 2 colorant.
Standard solutions
Standard stock solutions. – HCT, AMH, and TML stock solutions were prepared from 
100 mg of pure powder of each compound, accurately weighed, and transferred into a 500-
mL volumetric flask containing 1.0 mL ethanol. The solution was shaken well and there-
after diluted to the mark with distilled water. The stock solutions (200 mg L–1) were pro-
tected from light and kept at room temperature.
Validation of spectrofluorometric methods
Validation of the analytical methods was performed with respect to linearity, the 
limit of detection and quantitation, accuracy and precision, specificity and robustness, 
according to the ICH guidelines (15).
Linearity. – It was evaluated by analyzing five-level standard solutions for HCH, AMH, 
and TML in triplicate. Under the best experimental conditions, linear relationships be-
tween fluorescence intensity and concentration were achieved.
Limits of detection and quantitation (LOD&LOQ). – LOD is defined as 3.3σ/s, where σ is 
the standard deviation of replicate determinations of a blank, s is the slope of the regres-
sion line, while LOQ is defined as 10σ/s.
Accuracy and precision. – The model accuracy was evaluated by applying the proposed 
methods to the determination of three different concentrations of HCT (5, 7 and 11 mg 
L–1), AMH (0.030, 0.12 and 0.18 mg L–1) and TML (6, 16 and 24 mg L–1) (5 replicates). The 
determination of standard HCT, AMH and TML were carried out on the same day and 
for three consecutive days to test the repeatability and intermediate precision of the pro-
posed methods.
Specificity. – It was achieved with the analysis of ten synthetic mixtures of HCT/AMH 
and HCT/TML. The ratios of the training set mixtures were selected randomly with two 
mixtures (mixture 3: 10:1, m/m, HCT/AMH, and mixture 9:2:1, m/m, HCT/TML) reproducing 
the composition of the commercial tablets (Uniretic® and Timolide®). To ensure that these 
mixtures are mimicking the real samples, the prepared solutions were mixed with placebo 
powder (1 mL in 0.1 g powder), vortexed, stored for 10 minutes at 4 °C and then filtered 
(0.2-μm pore size).
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Emission spectra of HCT, AMH, and TML were partially overlapping in the region 
between 350 and 480 nm. A background subtraction approach was utilized to resolve this 
overlapping. This approach was applied to extract fluorescence spectra from Raman fluore-
scence in the case when the samples exhibited both fluorescence and Raman (16, 17).
In this case, it is necessary to neglect the effect of the internal absorption of one com-
pound from the emission of the second compound. In the analysis of mixture 1 that con-
tained HCT and AMH, emission of AMH was considered as background for the emission 
spectra of HCT/AMH solution. To fulfill such consideration, the fluorescence spectrum for 
AMH with concentration exactly equal to that in the mixture was recorded and stored as 
a background. The background subtraction facility in the software was used to extract the 
fluorescence of HCT from the emission of the mixture. A similar approach was used to 
evaluate the concentration of AMH in the mixture solution.
Robustness. – It was evaluated by studying the influence of small variations of the 
method conditions. These parameters include a variation of the excitation wavelength by 
± 2 nm, the solution temperature by ± 5 °C, and emission wavelength by ± 2 nm. Three 
concentrations (5, 7, 11 mg L–1) of standard HCT, (0.030, 0.12, 0.18 mg L–1) of standard AMH, 
and (6, 16, 24 mg L–1) of standard TML were analyzed and evaluated, and one parameter 
was changed at a time.
Commercial tablets analysis
Stock and working solutions of market samples were prepared by pounding 20 tablets 
of each formulation to a powder. An accurately weighed amount (1.8843 g) of Uniretic® was 





















Standard deviation of intercept (Sb)
0.9960.9990.987Correlation coefficient (R)
2.0087.2771.143Residual standard deviation (Sx/y)
0.0700.00130.0104LOD (mg L–1)b
0.2100.00400.312LOQ (mg L–1)b
a Y = sg + b, g  is a concentration in mg L–1 and Y is fluorescence intensity.
b LOD and LOQ were calculated as following: LOD = 3.3σ/s and LOQ = 10σ/s, where σ is the standard deviation of 
replicate determinations of blank, s is the slope of the regression line.
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transferred into a 250-mL volumetric flask containing 10 % aqueous ethanol. The solution 
was then sonicated for a few minutes and filtered using a 0.20-μm Whatman filter paper 
to remove insoluble components to get 215 mg L–1 HCT and 1076 mg L–1 AMH (as stock). 
An appropriate aliquot (0.60 mL) from the stock was transferred to a 25-mL volumetric 
flask to prepare 5.2 mg L–1 HCT and 25.8 mg L–1 AMH.
The stock and working solutions of Timolide® were prepared as previously described 
for Uniretic®. The stock solution was prepared by dissolving 0.4233 g of Timolide® powder 
in water. HCT and TMT were 10.8 mg L–1 and 24.7 mg L–1, resp., in water, after dilution.
The concentration of HCT, AMH and TMT in laboratory prepared mixtures and com-
mercial preparations were calculated using the parameters of the linear regression of each 
combination (Table I).
RESULTS AND DISCUSSION
Absorption and fluorescence spectra
Spectra of HCT, TML and AMH were separately recorded using water as a blank (see 
Fig. 1). Fig. 1 shows that absorption peaks of HCT were at 225, 270 and 316 nm with molar 
absorptivity of 3.45 × 104, 1.78 × 104 and 2.91 × 103 L mol–1 cm–1, resp., of TML at 207 and 295 
nm with molar absorptivity of 1.56 × 104 and 8.58 × 103 L mol–1 cm–1, resp., and of AMH at 
210, 285 and 365 nm with molar absorptivity of 8.80 × 104, 1.26 × 104 and 1.55 × 104 L mol–1 
cm–1, resp.
The quantitative analyses of HCT, TML and AMH in artificial mixtures and binary 
pharmaceutical formulations as HCT/TML and HCT/AMH were based on the direct mea-
surements of their fluorescence. HCT, TML and AMH exhibited maximum fluorescence at 
λem of 375 nm for HCT, 435 nm for TML and 415 nm for AMH after excitation at λex of 270, 
295 and 330 nm for HCT, TML and AMH, resp. (see Fig. 2). The fluorescence of these com-
pounds was greatly influenced by drug excipients which decreased the compounds’ quantum 














Fig. 1. Absorption spectra of 10 mg L–1 HCT against EtOH/H2O (solid line), 8 mg L–1 AMH against H2O 
(dot line) and 20 mg L–1 TML against H2O (dash line).
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yields (increased rates of radiationless decay) resulting in low sensitivity of detection. To 
minimize the influence of common excipients on fluorescence intensities of target com-
pounds, filtration and spectral data manipulation were carried out.
Validation of the spectrofluorometric methods
Linearity. – Under the best experimental conditions of dilution and concentrations, 
linear relationships were established in the range of 4–12 mg L–1 for HCT, 0.025–0.20 mg 
L–1 AMH and 5–35 mg L–1 TML. The respective regression equations for HCT, AMH and 
TML and their parameters such as slope (a) and standard deviation of the slope (Sa), inter-
cept (b) and standard deviation of the intercept (Sb), and residual standard deviation (Sx/y) 
were calculated (see Table I).
Limits of detection and quantitation. – The calculated limits of detection for HCT, AMH, 
and TML were 0.0104, 0.0013 and 0.070 mg L–1, resp. (Table I).
Accuracy and precision. – The model average percent recoveries ranged 99.9–100.4, 99.4–
100.3 and 99.0–100.3 % for HCT, AMH and TML, resp. The observed bias in the accuracy 
was acceptable since it was within the margin of errors. Thus, an adequate accuracy of the 
model was achieved. The precision of the method was judged by performing intra-day and 
inter-day analysis. The repeatability RSD was 0.6, 0.4 and 0.6 % for HCT, AMH and TML, 
resp. The intermediate precisions RSD was 0.7, 0.7 and 0.8 % for HCT, AMH and TML, resp. 
The RSDs below 1 % indicated reasonable repeatability and intermediate precision. The 
results are summarized in Table II.
Specificity. – The specificity of the developed method was performed on HCT/AMH 
and HCT/TML combinations in synthetic mixtures with added excipients, simulating the 
composition of drug formulations Uniretic® and Timolide®. The emission spectra of syn-
thetic mixtures displayed in Table III are presented in Figs. 3 and 4. Since emission spectra 
of HCT, AMH, and TML were partially overlapping in the region between 350 and 480 nm, 
background subtraction approach was utilized. For example, in the analysis of mixture 1 
which contained HCT and AMH (see Table III), emission of AMH or HCT was set as a 
Fig. 2. Fluorescence spectra of 12.0 mg L–1 HCT using λex = 270 nm (solid line), 0.20 mg L–1 AMH using 
λex = 330 nm (dot line), 20.0 mg L–1 TML using λex = 295 nm (dash line).
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Table II. Model accuracy and precision of the proposed spectrofluorometric methods for determination 














a Mean of five determinations.
















1 (4:1) 3.20 3.16 98.5 0.80 0.78 98.8
2 (8:1) 6.40 6.30 97.4 0.80 0.79 98.8
3 (10:1)b 8.00 7.92 99.0 0.80 0.78 97.5
4 (15:1) 12.0 11.4 96.4 0.80 0.77 96.3
5 (20:1) 16.0 15.4 96.3 0.80 0.76 95.0
Mean ± SD 97.5 ± 1.2 97.3 ± 0.6
HCT TML
6 (1:1) 10.0 9.90 98.6 10.0 9.69 96.8
7 (1:2) 10.0 9.94 99.3 20.0 19.5 97.5
8 (1:3) 10.0 9.67 96.6 30.0 28.7 95.6
9 (2:1)c 20.0 19.5 97.2 10.0 9.72 97.1
10 (3:1) 30.0 29.2 97.3 10.0 9.85 98.6
Mean ± SD 97.8 ± 1.1 97.1 ± 1.0
a Mean of four measurements.
b Synthetic mixture mimics the commercially available Uniretic®.
c Synthetic mixture mimics the commercially available Timolide®.
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Fig. 4. Emission of synthetic mixtures 6, 7, 8, 9 and 10 from Table III. Each mixture has two emission 
spectra A and B (A obtained using λex = 270 nm, B obtained using λex = 295 nm).
Fig. 3. Emission of synthetic mixtures 1, 2, 3, 4 and 5 from Table III. Each mixture has two emission 
spectra, A and B (A obtained using λex = 270 nm, B obtained using λex = 330 nm).
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background for the emission spectra of HCT/AMH mixture solution to extract emission of 
the other component (mixture 1: A and B, resp., Fig. 3).
The analysis of the synthetic mixtures showed acceptable mean recoveries of 97.8 ± 1.6, 
98.5 ± 0.5 and 97.1 ± 1.0 % for HCT, AMH and TML, resp. Moreover, the specificity was also 
evaluated regarding possible spectral interferences from the excipients. The emission 
spectra of commercial tablets solutions did not show any additional peaks when compared 
to the emission of synthetic mixtures. The concentration of each individual component in 
the synthetic mixtures was calculated from the regression equation of the calibration 
curve (see Table III).
Robustness. – The solutions were solely prepared in water. The pH of the spiked solu-
tions (standards and mixtures) was above 7, the solution acidity was not modified at any 
condition to ensure the integrity of the active ingredients. Changing the solution composi-
tion by adding organic solvent or inorganic salts was completely excluded to ensure meth-
od greenness.
Small changes to the method conditions, including temperature, and excitation and 
emission wavelength, did not affect the recovery of the drugs. Recoveries ranged 97.8–101.6 % 
and RSDs were 0.2-1.8 %, which indicated that the method was robust enough (see Table IV).
Table IV. Results of robustness
Parameter
Recovery ± RSD (%)
HCT a AMH b TMLc






























99.9 ± 0.97 100.0 ± 0.87
101.2 ± 0.76 99.9 ± 1.5
100.4 ± 1.2
a HCT (n = 5), three concentrations (5,7,11 mg L–1), excitation and emission were 270 and 375 nm, resp.
b AMH (n = 5), three concentrations (0.030, 0.12, 0.18 mg L–1), excitation and emission were 330 and 415 nm, resp.
c TML (n = 5), three concentrations (6, 16, 24 mg L–1), excitation and emission were 295 and 435 nm, resp.
d The ambient temperature was 22 °C.
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Table V. Determinations of HCT, AMT, TML in pharmaceutical preparations by proposed 
and literature methods
Proposed method Literature methoda
AMH HCT AMH HCT
Uniretic® 
(50 mg AMH  + 5 mg HCT)
      Found (mg)b 47.87 ± 0.88 4.52 ± 0.47 48.90 ± 0.91 4.60 ± 0.90
      t (2.23)c 1.99 0.193
      F (5.05)c 1.07 3.67
TML HCT TML HCT
Timolide® 
(25 mg TML + 10 mg HCT)
      Found (mg)b    23.52 ± 0.36 9.74 ± 0.14 23.71 ± 0.19 9.88 ± 0.72
      t (2.23)c 1.14 0.467
      F (5.05)c 3.59 3.08
a Chromatographic method using reversed-phase column (ref. 23); b Mean ± SD, n = 6; c Tabulated t- and F-values at 
p = 0.05.
Table VI. Selected published detection limits of HCT, TML and AMH










a RP C18 base deactivated silica column with a mobile phase consisting of triethylamine (pH 3.0) adjusted with ortho-
phosphoric acid and acetonitrile, the flow rate of 1.4 mL min–1; b Generation of ratio spectra of two-drug combina-
tions, candesartan cilexetil and HCT. HCT was estimated using the amplitudes between 251 and 276 nm; c RP-HPLC 
using a Shim-pack C18 column at a flow rate of 1 mL min–1. The mobile phase consisted of water and acetonitrile in 
the ratio of 35:65, using a UV detector at 281 nm; d Sorption of amiloride on a cation-exchange resin at pH 4.0 and direct 
measurement of its intrinsic UV absorbance in the solid phase at 362 nm and 412 nm; e BDS Hypersil phenyl column 
and a mobile phase consisting of acetonitrile and 25 mmol L–1 phosphate buffer, pH 4.0 (50:50, V/V), 1.2 mL min–1, UV 
detection at 210 nm; f Derivative spectrophotometry using the zero-crossing measurements. Linear calibration 
graphs of first-derivative values at 250.3 nm for dorzolamide hydrochloride and 315.8 nm for TML.
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Analysis of commercial formulations
The proposed methods were applied to the analysis of two commercially available 
drug formulations, Uniretic® and Timolide®. The background subtraction method was 
applied to determine the concentration of each individual compound in those formula-
tions. The recovered amount of drugs from tablets was in a good agreement with claimed 
values (Table V). The amount of AMH and HCT found in Uniretic®, expressed in mg per 
tablet, was 47.87 ± 0.88 for AMH and 4.52 ± 0.47 for HCT with label compliance (± SD) of 
95.6 ± 0.7 and 90.2 ± 0.4 %, resp., while the amount of TML and HCT in Timolide® was 23.52 
± 0.36 and 9.74 ± 0.41 mg, giving a label compliance of 94.1 ± 0.2 and 97.4 ± 0.7 % for TML 
and HCT, resp.
Statistical analysis of the results obtained by the proposed method versus the HPLC 
method (23) showed no significant differences in performance at p = 0.05 as indicated by 
the Student’s t-test and variance F-test for AMH/HCT and TML/HCT drug combinations 
(Table V). This indicates that the proposed method is applicable to quantitative analyses.
Comparison of detection limits of this work and previously published values for HCT, 
AMH and TML is listed in Table VI.
CONCLUSIONS
Spectrofluorometric methods for the quantitative analysis of HCT, AMH and TML in 
combined pharmaceutical formulations were evaluated. The methods have many advan-
tages such as simplicity, rapidity, selectivity and reasonable sensitivity. They offer low-cost 
analyses, using chemicals and equipment available in any analytical laboratory. The meth-
od for HCT/AMH and HCT/TML analysis was found reliable for routine applications. Fur-
ther studies on other drug combinations are under the way. 
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